What is Aardvark Therapeutics, Inc.'s (AARD) StockRank?

MoatMap's StockRank for Aardvark Therapeutics, Inc. (AARD) is 7/100, with a Strong Sell signal. This is a composite score combining Quality (37), Value (41), and Momentum (11) factor ranks across MoatMap's 20,000+ stock universe.

Does Aardvark Therapeutics, Inc. have an economic moat?

Aardvark Therapeutics, Inc. (AARD) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Aardvark Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Aardvark Therapeutics, Inc. (AARD) is Strong Sell, based on a StockRank of 7/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Aardvark Therapeutics, Inc. in?

Aardvark Therapeutics, Inc. (AARD) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

AARD

STRONG SELLREMOVE

Aardvark Therapeutics, Inc. · Healthcare · United States · $92M · Avg Vol: $642K/d

StockRank

P/E (TTM)

—

ROE

-58.8%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Aardvark Therapeutics is a micro-cap clinical-stage biopharmaceutical company. It lacks commercialized products, has zero revenues, and is highly speculative, failing all of our quality and margin of safety criteria.

COMPANY DESCRIPTION

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for metabolic and inflammatory diseases. The company's lead program targets bitter taste receptors (TAS2R) to regulate appetite and metabolic function, offering a unique mechanism of action in the obesity space. Its competitive moat is supported by a proprietary drug discovery platform and a robust intellectual property portfolio.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-1.39	-0.56	-0.96	-2.93	—
Shares	21M	21M	22M	22M	+2.0%
Debt	262,000	162,000	779,000	441,000	19.0%
Equity	-28M	-35M	-55M	107M	—
Op CF	-11M	-6M	-18M	-54M	—
Inv CF	-1M	0	-12M	-50M	—
Fin CF	225,000	0	82M	89M	—

PRICE (1M)-35.1%

SMA 50SMA 200

$3.82

RSI (14)

38.7

52W High

$17.94

From 52W High

0.2%

SCORE BREAKDOWN

Quality

ROIC

-58.8%11.4

ROE

-58.8%14.9

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

-29.4%10.1

Piotroski

—28.7

Int. Cover

—N/A

D/E Ratio

0.00x94.0

Current Ratio

8.06x82.9

Value

P/E (TTM)

—N/A

EV/EBITDA

0.1x62.6

P/FCF

—N/A

P/B

1.0x79.4

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

21%2.4

RS 6M

-83%11.1

SMA 50/200

0.50x1.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-1%20.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$92M

P/E (Forward)

-1.2x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AARD are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
AARD	Aardvark Therapeutics, Inc.(you)	$92M	7	STRONG SELL
ANIX	Anixa Biosciences, Inc.	$91M	7	STRONG SELL
2257.HK	Sirnaomics Ltd.	$82M	7	STRONG SELL
PEPG	PepGen Inc.	$104M	7	STRONG SELL
CGTX	Cognition Therapeutics, Inc.	$107M	9	STRONG SELL
BMEA	Biomea Fusion, Inc.	$100M	10	STRONG SELL
GOSS	Gossamer Bio, Inc.	$79M	9	STRONG SELL
GANX	Gain Therapeutics, Inc.	$86M	3	STRONG SELL
SGMO	Sangamo Therapeutics, Inc.	$87M	3	STRONG SELL
ALDX	Aldeyra Therapeutics, Inc.	$106M	5	STRONG SELL

Peer medians: ROE -22.4% · P/E 25.3x · Gross margin 44.3%

Aardvark Therapeutics, Inc. (AARD) — Stock Score Summary

Aardvark Therapeutics, Inc. (AARD) has a MoatMap StockRank of 7/100 based on Quality (37/100), Value (41/100), and Momentum (11/100) factor scores. The current signal is STRONG SELL. Aardvark Therapeutics is a micro-cap clinical-stage biopharmaceutical company. It lacks commercialized products, has zero revenues, and is highly speculative, failing all of our quality and margin of safety criteria.

Key Financial Metrics

Price	$3.82
Market Cap	$92M
P/E (Forward)	-1.20
Price/Book	0.98
Return on Equity	-58.8%
Return on Invested Capital	-58.8%
Debt/Equity	0.39
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-34M

Aardvark Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Aardvark Therapeutics, Inc.’s (AARD) StockRank?: MoatMap’s StockRank for Aardvark Therapeutics, Inc. (AARD) is 7/100, with a Strong Sell signal. It is a composite of Quality (37), Value (41), and Momentum (11) factor ranks across MoatMap’s 20,000+ stock universe.
Does Aardvark Therapeutics, Inc. have an economic moat?: Aardvark Therapeutics, Inc. (AARD) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Aardvark Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Aardvark Therapeutics, Inc. (AARD) is Strong Sell, based on a StockRank of 7/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Aardvark Therapeutics, Inc. in?: Aardvark Therapeutics, Inc. (AARD) operates in the Healthcare sector, specifically the Biotechnology industry (United States).